What do deep neural networks and cancer immunotherapy have in common?
Just two years after its founding, biotech startup Immunai has raised $60 million in Series A funding, bringing its total raised to over $80 million. Despite its youth, Immunai has already established
For the past two years the founding team of Immunai had been working stealthily to develop a new technology to map the immune system of any patient. Founded by Noam Solomon, a Harvard and MIT-educated
Scientists in collaboration with tech billionaire Sean Parker's Institute for Cancer Immunotherapy may have found a way to predict whether melanoma patients will respond to treatments that target the
Sean Parker, the self-made billionaire who, at the tender age of 19, sparked the digital music revolution, has been at the forefront of some of the most meaningful disruptions of our day from file sha